Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of Dupilumab in Severe Asthma
Fabio Luigi Massimo Ricciardolo, Francesca Bertolini, Vitina Carriero
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1096-1096
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
Corrado Pelaia, Enrico Heffler, Claudia Crimi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 83
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Corrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity
Diya Garg, Loretta G. Que, Jennifer L. Ingram
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 9
Interleukin inhibitors and the associated risk of candidiasis
Sabir Khan, Hazrat Bilal, Muhammad Nadeem Khan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
Koichi Andō, Y Fukuda, Akihiko Tanaka, et al.
Cells (2022) Vol. 11, Iss. 5, pp. 819-819
Open Access | Times Cited: 26
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment
Valentina D’Aiuto, Ilaria Mormile, Francescopaolo Granata, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1729-1729
Open Access
Novel Biological Therapies for Severe Asthma Endotypes
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Biomedicines (2022) Vol. 10, Iss. 5, pp. 1064-1064
Open Access | Times Cited: 21
Investigational anti IL-13 asthma treatments: a 2023 update
Maria Gabriella Matera, Josuel Ora, Luigino Calzetta, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 373-386
Closed Access | Times Cited: 12
Multi-omics analysis identified IL-4-induced IL1RL1high eosinophils characterized by prominent cysteinyl leukotriene metabolism
Keeya Sunata, Jun Miyata, Yusuke Kawashima, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1277-1288
Open Access | Times Cited: 4
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)
Jorge Máspero, Martti Antila, A. Deschildre, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 12, pp. 3303-3312
Open Access | Times Cited: 4
Modern Possibilities of Usage Dupilumab in Children
Anna A. Kosova, Anastasiya V. Fayans, Aishan Е. Ibaduiiaeva, et al.
Педиатрическая фармакология (2025) Vol. 21, Iss. 6, pp. 520-533
Open Access
Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission
Mona Al‐Ahmad, Asmaa Ali, Wafaa Talat
BMC Pulmonary Medicine (2025) Vol. 25, Iss. 1
Open Access
The role of ILC2s in asthma combined with atopic dermatitis: bridging the gap from research to clinical practice
Yang Luo, Yu Deng, Feng Yang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Navigating biologic therapies in elderly asthma
HyeIn Ji, Laren Tan, George W. Hafzalla, et al.
Respiratory Medicine (2024) Vol. 227, pp. 107655-107655
Closed Access | Times Cited: 3
Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome
Dimitri Poddighe, Elena Kovzel
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 6845-6853
Open Access | Times Cited: 23
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
Corrado Pelaia, Giulia Pelaia, Claudia Crimi, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 974-974
Open Access | Times Cited: 14
Defining response to therapy with biologics in severe asthma: from global evaluation to super response and remission
Andriana Ι. Papaioannou, Evangelia Fouka, Κonstantinos Bartziokas, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 6, pp. 481-493
Closed Access | Times Cited: 8
Dupilumab and tezepelumab in severe refractory asthma: new opportunities
Beatrice Ragnoli, Jaymin B. Morjaria, Patrizia Pignatti, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210973-204062232210973
Open Access | Times Cited: 12
Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
Zaid Zoumot, Nasser Al Busaidi, Wail Tashkandi, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1665-1679
Open Access | Times Cited: 12
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9
A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts
Valerie Jaroenpuntaruk, Thanai Pongdee
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 5, pp. 1394-1396
Closed Access | Times Cited: 1
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps
Shama Shishodia, Nora Haloob, Claire Hopkins
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 491-502
Closed Access | Times Cited: 1
Rhinovirus infection of airway epithelial cells uncovers the non-ciliated subset as a likely driver of genetic risk to childhood-onset asthma
Sarah Djeddi, Daniela Fernandez‐Salinas, George Huang, et al.
Cell Genomics (2024) Vol. 4, Iss. 9, pp. 100636-100636
Open Access | Times Cited: 1
Genome-wide DNA methylation profi le and expression of TLR2, TLR9, IL4, IL13 genes in pediatric patients with atopic dermatitis
Elizaveta Bystritskaya, Nikolay N. Murashkin, Alexander I. Materikin, et al.
Immunologiya (2022) Vol. 43, Iss. 3, pp. 255-265
Open Access | Times Cited: 3
Is Dupilumab a chance for patients with moderate to severe atopic dermatitis? Literature review
Paweł Iwańczuk
Journal of Education Health and Sport (2024) Vol. 63, pp. 84-94
Open Access
Page 1 - Next Page

Scroll to top